Results 201 to 210 of about 36,503 (286)

Influence of Genetic Variation of GST, CYP, and ABC on the Safety and Efficacy of Cyclophosphamide-Based Therapy. [PDF]

Clin Transl Sci
Yao ZW, Li QL, Hu WF, Pan LH, Wu JW, Ren WL, Jia HT, Wang PP, Fu ZY, Zhu H.   +9 more
europepmc   +1 more source

Erradicación de H. pylori y su relación con la resistencia a los antibióticos y el estatus de CYP2C19 [PDF]

, 2007
Elvira Garza‐González, Emmanuel González, Manuel Martínez-Vazquez, Guillermo I. Pérez‐Pérez, Gerardo González, Héctor Jesús Maldonado-Garza, Francisco Javier Bosques Padilla   +6 more
openalex   +1 more source

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting [PDF]

, 2017
Beitelshees, AL, Blake, KV, Cavallari, LH, Dressler, LG, Duarte, JD, Eichmeyer, JN, Elsey, A, Empey, PE, Franciosi, JP, Hicks, JK, Holmes, AM, Jeng, LJB, Johnson, JA, Lee, CR, Lima, JJ, Limdi, NA, Modlin, J, Obeng, AO, Peterson, JF, Petry, N, Pratt, VM., Skaar, TC, Tuteja, S, Voora, D, Wagner, M, Weitzel, KW, Wilke, RA   +26 more
core   +1 more source

Comparative in vitro assessment of CYP2C19 inhibition by ilaprazole and conventional proton pump inhibitors using a high throughput fluorometric assay. [PDF]

Sci Rep
Priyadharshini A, Vijayakumar TM, Damodharan N, Vasanth KM, Elaiyaraja A.   +4 more
europepmc   +1 more source

Advances in the Clinical Use of Clopidogrel: A Review of Individualized Treatment Strategies and Monitoring Optimization Based on Genetic Polymorphisms. [PDF]

Pharmgenomics Pers Med
Dou N, Ma H, Zhang P, Lu R, Hang J, Sun J.   +5 more
europepmc   +1 more source

CYP2C19 pharmacogenetics in PPI therapy of GERD: Variant alleles predict gastric acid suppression, but not esophageal acid exposure or reflux symptoms

, 2003
Laurence J. Egan, Gennett M. Myhre, Dennis C. Mays, Patricia P. Kammer, Ross Dierkhising, Joseph A. Murray   +5 more
openalex   +1 more source

Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population [PDF]

, 2008
Katsuyoshi Sugimoto, Tsukasa Uno, Hiroshi Yamazaki, Tomonori Tateishi   +3 more
openalex   +1 more source

Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes. [PDF]

Hum Genomics
Johansson I, Lu Y, Zhou Y, Krebs K, Akcan M, Milani L, Ingelman-Sundberg M.   +6 more
europepmc   +1 more source

A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications. [PDF]

NPJ Genom Med
Shorbaji A, Pushparaj PN, Al-Ghafari AB, Mira LS, Basabrain MA, Naseer MI, Ahmed F, Abu-Elmagd M, Rasool M, Bakhashab S.   +9 more
europepmc   +1 more source

Polimorfizam CYP2C19 u bolesnika s kardioembolijskim događajem

, 2015
CYP2C19 is a hemoprotein participating in the first phase of biotransformation of xenobiotics and endogenous molecules and represents a large gene family CYP2C. The total share of the first phase of metabolic biotransformation with CYP2C9 make up 15%. CYP2C19 gene locus is located on chromosome 10q24 and consists of 9 exons.
openaire   +2 more sources